Background BCG vaccine has shown consistently high efficacy against childhood
tuberculous meningitis and miliary tuberculosis, but variable efficacy against adult …

Background Many countries offer a second BCG vaccination to prevent tuberculosis,
although there is little evidence of whether this confers additional protection. BCG …

Background There are no data on the feasibility and cost-effectiveness of using second-line
drugs to treat patients with chronic tuberculosis, many of whom are infected with multidrug …

Studies of disease burden have reaffirmed that tuberculosis is among the top 10 causes of
death in the world. The tuberculosis epidemic in most countries could eventually be brought …

Background Multidrug-resistant tuberculosis (MDR-TB) is an important global health
problem, and a control strategy known as DOTS-Plus has existed since 1999. However …

This paper assesses the impact of economic studies on TB control during the period 1982–
2002, with a focus on cost and cost-effectiveness studies. It begins by identifying broad …

Background. Resistance to commonly used antituberculosis drugs is emerging worldwide.
Conventional drug-susceptibility testing (DST) methods are slow and demanding …

Background µ. Studies of different vaccine constructs have demonstrated variable efficacy
against Mycobacterium tuberculosis in animal models. Despite the fact that these vaccines …

ABSTRACT Introduction: Bacillus Calmette-Guérin (BCG) is the only licensed vaccine for
tuberculosis, but its effectiveness is limited and varies by age. New candidate vaccines are …

The BCG vaccine was introduced in 1921 and remains the only licensed vaccine for the
prevention of TB worldwide. Despite its extensive use, the BCG vaccine lacks the ability to …